GeneralConnection.com ➔ Dictionary
Dictionary Search

dyne

Synonyms

Noun

1. force unit

Usage
Atlas funds linked to Dyne (DYN) director sell 504,695 shares - Stock Titan
Dyne Therapeutics(DYN.US) Director Sells US$10.71 Million in Common Stock - Moomoo
Form 4 Dyne Therapeutics Inc For: 30 June By Investing.com - Investing.com Canada
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy - NeurologyLive
Dyne hopes to bring new treatment for DM1 to US market in 2028 - Muscular Dystrophy News
Tribute Wall | Diane Van Dyne - Thomas Funeral Homes
Price to sales forward of Dyne Therapeutics, Inc. – NASDAQ:DYN - TradingView
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain? - simplywall.st
Dyne Therapeutics Expands Debt Facility of Up to $400MM with Hercules Capital - ABF Journal
Dyne therapeutics director Jason Rhodes sells $10.7m in stock - Investing.com UK
TD Cowen Initiates Dyne Therapeutics at Buy - Moomoo
Dyne Therapeutics (DYN) director-linked funds sell 267,760 shares - Stock Titan
MDA 2026: Dyne therapy boosts strength, cognition in DM1 - Muscular Dystrophy News
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - Moomoo
Dyne Therapeutics (NASDAQ: DYN) CFO sells 2,362 shares to cover taxes - Stock Titan
Dyne commences Phase III HARMONIA trial for DM1 therapy - Clinical Trials Arena
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Yahoo Finance
Dyne Therapeutics Appoints Barry Greene to Board of Directors - GlobeNewswire
Dyne Robert Hoenie Obituary (2026) - Celina, OH - W.H. Dick & Sons Hellwarth Funeral Homes - Legacy obituary
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Yahoo Finance
Dyne Therapeutics stock initiated at buy by TD Cowen on platform - Investing.com
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval - Muscular Dystrophy News
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) - GlobeNewswire
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Dyne Therapeutics (DYN) Adds Barry Greene And Expands Funding, Is The Stock Still A Bargain? - Sahm
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development - NeurologyLive
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com South Africa
Dyne, citing positive trial data, to ask FDA to approve DMD therapy - Muscular Dystrophy News
Dyne Therapeutics Insider Sold Shares Worth $5,646,497, According to a Recent SEC Filing - marketscreener.com
Dyne Therapeutics (DYN) director-affiliated fund sells 263,962 shares under 10b5-1 plan - Stock Titan
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com South Africa
Dyne Therapeutics Secures Up to $125 Million in Additional Borrowing Capacity for Clinical Advancements - Quiver Quantitative
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - GlobeNewswire
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data - BioSpace
Dyne Therapeutics Expands Hercules Capital Debt Facility to Up to $400 Million - citybiz
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO - GlobeNewswire
WilmerHale Advises Dyne Therapeutics on its $402.5 Million Public Offering of Common Stock - WilmerHale
Dyne Therapeutics Stock Gains 4.5% After BLA Filing for DMD Therapy - Yahoo Finance
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline? - Yahoo Finance
Dyne Primed for Suitors Amid Novartis’ $12B Avidity Acquisition - BioSpace
Dyne Therapeutics director Kersten sells $5.46 million in shares - Investing.com
Dyne Therapeutics(DYN.US) Director Sells US$5.46 Million in Common Stock - Moomoo
Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD - NeurologyLive
Dyne Therapeutics adds ex-Sage CEO Barry Greene to board - Stock Titan
Dyne to seek accelerated approval of DMD drug on Phase I/II data - Clinical Trials Arena
Patty Lou (Crum) Van Dyne Obituary Apr 26, 2026 - wilsonfuneralhomes.com
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com Canada
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean - The Motley Fool
Erick Lucera files Form 144 to sell DYN shares (DYN) - Stock Titan
Dyne Therapeutics (DYN) Is Up 12.1% After Expanding Debt Facility And Adding Veteran Biotech Director - simplywall.st
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Yahoo Finance
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Yahoo Finance
Biotech Dyne adds $400M debt to advance two rare disease drugs - Stock Titan
Dyne Therapeutics plans to file for approval for next-generation Duchenne drug - statnews.com
Dyne readies FDA push after DMD exon 51 med excels in trial - Fierce Biotech
Dyne Therapeutics (DYN) RBC Capital Markets Global Healthcare Conference 2026 summary - Quartr
Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data - Yahoo Finance
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com Canada
Dyne Therapeutics: Why The $350M Public Offering Was Critical (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ: DYN) director Barry Greene files initial Form 3 - Stock Titan
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission (DYN) - Seeking Alpha
Number of shareholders of Shandong Wit Dyne Health Co., Ltd. Class A – SZSE:000915 - TradingView
Dyne awards stock options, RSUs to 6 newly hired employees - Stock Titan
Dyne Therapeutics’ Exon Skipping Duchenne Therapy Delivers Good Results - Inside Precision Medicine
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Yahoo Finance
Director at Dyne Therapeutics (DYN) awarded 57,463 stock options vesting over 3 years - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com Australia
Dyne Therapeutics appoints Barry Greene to board of directors - Investing.com
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com UK
Entity tied to Dyne (DYN) director sells 84K pre-planned shares - Stock Titan
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Dyne Therapeutics (NASDAQ: DYN) CEO logs automatic RSU tax sale - Stock Titan
Form 4 Dyne Therapeutics Inc For: 24 June By Investing.com - Investing.com Nigeria
Global trial testing Dyne’s Z-rostudirsen for boys with DMD now underway - Muscular Dystrophy News
Dyne Therapeutics elects Barry E. Greene to Board as Class I director - TradingView
Dyne Therapeutics Insider Sold Shares Worth $5,464,611, According to a Recent SEC Filing - marketscreener.com
Dyne Therapeutics DM1 Trial Reaches Pivotal Stage With ACHIEVE Enrollment - simplywall.st
Dyne therapeutics director Jason P Rhodes sells $5.65m in stock - Investing.com Australia
Barry Greene joins Dyne Therapeutics (DYN) board with new option grant - Stock Titan
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Yahoo Finance
Why Dyne Therapeutics (DYN) Is Up 11.4% After Completing ACHIEVE Cohort Enrollment And Expanding Share Count - Sahm
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
PetAg® Launches Dyne™ Soft Chews Nationwide, Bringing Science‑Backed Daily Wellness to Dogs Everywhere - PR Newswire
Dyne Therapeutics (NASDAQ: DYN) boosts Hercules loan capacity to $400M - Stock Titan
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - The Motley Fool
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - Yahoo Finance
Form 4 Dyne Therapeutics Inc For: 26 June By Investing.com - Investing.com UK
Dyne’s Exon Skipper Delivers ‘Best Ever’ Functional Outcomes in Early DMD Study - BioSpace
Dyne Therapeutics Expands Hercules Loan Facility to $400 Million, Draws $50 Million Tranche - TradingView
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) - Yahoo Finance
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - Yahoo Finance
Dyne therapeutics CEO John Cox sells $49,179 in stock - Investing.com
A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress - Yahoo Finance
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU tax withholding - Stock Titan
Dyne Therapeutics Initiates Phase 3 FORZETTO Trial of Zeleciment Rostudirsen for Duchenne Muscular Dystrophy - Quiver Quantitative
Form 144 Dyne Therapeutics For: 25 June By Investing.com - Investing.com Canada
Foreign Language Equivalents
Foreign Language Equivalents of 'dyne'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
dyyne,   dynw,   syne,   dyen,   dtne,   dyn,   ydne,   dynee,   yne,   dynr,   dybe,   dnye,   dynne,   fyne,   dyme,   dune,   ddyne,   dne,   dye
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z